Display options
Cite
Marsh GA, McAuley AJ, Au GG, et al. ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets. NPJ Vaccines. 2021;6(1):67doi: 10.1038/s41541-021-00315-6.
Marsh, G. A., McAuley, A. J., Au, G. G., Riddell, S., Layton, D., Singanallur, N. B., Layton, R., Payne, J., Durr, P. A., Bender, H., Barr, J. A., Bingham, J., Boyd, V., Brown, S., Bruce, M. P., Burkett, K., Eastwood, T., Edwards, S., Gough, T., Halpin, K., Harper, J., Holmes, C., Horman, W. S. J., van Vuren, P. J., Lowther, S., Maynard, K., McAuley, K. D., Neave, M. J., Poole, T., Rootes, C., Rowe, B., Soldani, E., Stevens, V., Stewart, C. R., Suen, W. W., Tachedjian, M., Todd, S., Trinidad, L., Walter, D., Watson, N., Drew, T. W., Gilbert, S. C., Lambe, T., & Vasan, S. S. (2021). ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets. NPJ vaccines, 6(1), 67. https://doi.org/10.1038/s41541-021-00315-6
Marsh, Glenn A, et al. "ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets." NPJ vaccines vol. 6,1 (2021): 67. doi: https://doi.org/10.1038/s41541-021-00315-6
Marsh GA, McAuley AJ, Au GG, Riddell S, Layton D, Singanallur NB, Layton R, Payne J, Durr PA, Bender H, Barr JA, Bingham J, Boyd V, Brown S, Bruce MP, Burkett K, Eastwood T, Edwards S, Gough T, Halpin K, Harper J, Holmes C, Horman WSJ, van Vuren PJ, Lowther S, Maynard K, McAuley KD, Neave MJ, Poole T, Rootes C, Rowe B, Soldani E, Stevens V, Stewart CR, Suen WW, Tachedjian M, Todd S, Trinidad L, Walter D, Watson N, Drew TW, Gilbert SC, Lambe T, Vasan SS. ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets. NPJ Vaccines. 2021 May 10;6(1):67. doi: 10.1038/s41541-021-00315-6. PMID: 33972565; PMCID: PMC8110954.
Copy Download .nbib Format: NLM
Share it on

NPJ Vaccines. 2021 May 10;6(1):67. doi: 10.1038/s41541-021-00315-6.

ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets.

NPJ vaccines

Glenn A Marsh, Alexander J McAuley, Gough G Au, Sarah Riddell, Daniel Layton, Nagendrakumar B Singanallur, Rachel Layton, Jean Payne, Peter A Durr, Hannah Bender, Jennifer A Barr, John Bingham, Victoria Boyd, Sheree Brown, Matthew P Bruce, Kathie Burkett, Teresa Eastwood, Sarah Edwards, Tamara Gough, Kim Halpin, Jenni Harper, Clare Holmes, William S J Horman, Petrus Jansen van Vuren, Suzanne Lowther, Kate Maynard, Kristen D McAuley, Matthew J Neave, Timothy Poole, Christina Rootes, Brenton Rowe, Elisha Soldani, Vittoria Stevens, Cameron R Stewart, Willy W Suen, Mary Tachedjian, Shawn Todd, Lee Trinidad, Duane Walter, Naomi Watson, Trevor W Drew, Sarah C Gilbert, Teresa Lambe, S S Vasan

Affiliations

  1. CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  2. Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  3. CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia. [email protected].
  4. Department of Health Sciences, University of York, York, UK. [email protected].

PMID: 33972565 PMCID: PMC8110954 DOI: 10.1038/s41541-021-00315-6

Abstract

Vaccines against SARS-CoV-2 are likely to be critical in the management of the ongoing pandemic. A number of candidates are in Phase III human clinical trials, including ChAdOx1 nCoV-19 (AZD1222), a replication-deficient chimpanzee adenovirus-vectored vaccine candidate. In preclinical trials, the efficacy of ChAdOx1 nCoV-19 against SARS-CoV-2 challenge was evaluated in a ferret model of infection. Groups of ferrets received either prime-only or prime-boost administration of ChAdOx1 nCoV-19 via the intramuscular or intranasal route. All ChAdOx1 nCoV-19 administration combinations resulted in significant reductions in viral loads in nasal-wash and oral swab samples. No vaccine-associated adverse events were observed associated with the ChAdOx1 nCoV-19 candidate, with the data from this study suggesting it could be an effective and safe vaccine against COVID-19. Our study also indicates the potential for intranasal administration as a way to further improve the efficacy of this leading vaccine candidate.

References

  1. Nature. 2020 Oct;586(7830):578-582 - PubMed
  2. Front Immunol. 2018 May 02;9:934 - PubMed
  3. Lancet Microbe. 2020 Sep;1(5):e218-e225 - PubMed
  4. PLoS One. 2012;7(7):e40385 - PubMed
  5. Nat Commun. 2021 Jan 4;12(1):81 - PubMed
  6. Cell Host Microbe. 2020 May 13;27(5):704-709.e2 - PubMed
  7. Nat Commun. 2020 Aug 14;11(1):4081 - PubMed
  8. Sci Adv. 2020 Jun 10;6(24):eaba8399 - PubMed
  9. Lancet Infect Dis. 2020 Jul;20(7):816-826 - PubMed
  10. Nature. 2020 Mar;579(7798):270-273 - PubMed
  11. Med J Aust. 2020 Jun;212(10):459-462 - PubMed
  12. Nature. 2021 Apr;592(7852):116-121 - PubMed
  13. Lancet. 2020 Aug 15;396(10249):467-478 - PubMed
  14. Euro Surveill. 2020 Jan;25(3): - PubMed
  15. N Engl J Med. 2020 Feb 20;382(8):727-733 - PubMed
  16. mBio. 2020 May 22;11(3): - PubMed
  17. Nat Commun. 2020 Jul 8;11(1):3496 - PubMed
  18. Sci Rep. 2019 Nov 8;9(1):16292 - PubMed
  19. Science. 2020 May 29;368(6494):1016-1020 - PubMed
  20. Nat Microbiol. 2020 Apr;5(4):536-544 - PubMed
  21. NPJ Vaccines. 2020 Oct 8;5:96 - PubMed
  22. Lancet. 2021 Dec 19;396(10267):1979-1993 - PubMed

Publication Types